Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-dose study of NNC6022-0001 in healthy adults
NL-OMON60184Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of NNC6022-0001 in cardiometabolic disease, sponsored by Novo Nordisk. Primary endpoint: Primary endpoint(s). Started Mar 2024; status: completed.
02
Drugs
NNC6022-0001
03
Conditions
cardiometabolic disease
Beyond the preview
Go deeper on NL-OMON60184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60184.